Objective: Minocycline, a tetracycline antibiotic, has shown anti-inflammatory effects in cerebral ischemia and neurodegenerative disease; however, the molecular mechanisms underlying this effect have not been clearly identified. Since NLRP3 inflammasome activation controls the maturation and release of proinflammatory cytokines, especially interleukin-1β (IL-1β) and IL-18 in ischemia stroke, we suppose that minocycline may be involved in the regulation of NLRP3 inflammasome activation. Methods: We investigated the effects of minocycline on NLRP3 inflammasome activation using the transient middle cerebral artery occlusion (tMCAO) mouse model and an in vitro oxygen-glucose deprivation/reoxygenation injury model in BV2 microglial cells. Results: We found that minocycline administrated 1 h after reperfusion can improve neurological disorder, reduce infarct volume, and alleviate cerebral edema. Meanwhile, we showed that minocycline prevented the activation of microglias and attenuated NLRP3 inflammasome signaling after tMCAO injury. Furthermore, we found that the pretreatment of minocycline significantly inhibited signal 1 and signal 2 of NLRP3 inflammasome activation in BV2 cells. Conclusion: We demonstrated that minocycline can ameliorate ischemia-induced brain damage via inhibiting NLRP3 inflammasome activation.

Keywords:
Minocycline, Microglia, NLRP3 inflammasome
1.
Moretti A, Ferrari F, Villa RF: Neuroprotection for ischaemic stroke: current status and challenges. Pharmacol Ther 2015;146:23-34.
2.
Doyle KP, Simon RP, Stenzel-Poore MP: Mechanisms of ischemic brain damage. Neuropharmacology 2008;55:310-318.
3.
Kleindorfer D, Xu Y, Moomaw CJ, Khatri P, Adeoye O, Hornung R: US geographic distribution of RT-PA utilization by hospital for acute ischemic stroke. Stroke 2009;40:3580-3584.
4.
de Rivero Vaccari JP, Dietrich WD, Keane RW: Activation and regulation of cellular inflammasomes: gaps in our knowledge for central nervous system injury. J Cereb Blood Flow Metab 2014;34:369-375.
5.
Trendelenburg G: Molecular regulation of cell fate in cerebral ischemia: role of the inflammasome and connected pathways. J Cereb Blood Flow Metab 2014;34:1857-1867.
6.
Fann DY, Lee SY, Manzanero S, Tang SC, Gelderblom M, Chunduri P, Bernreuther C, Glatzel M, Cheng YL, Thundyil J, Widiapradja A, Lok KZ, Foo SL, Wang YC, Li YI, Drummond GR, Basta M, Magnus T, Jo DG, Mattson MP, Sobey CG, Arumugam TV: Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke. Cell Death Dis 2013;4:e790.
7.
Yang F, Wang Z, Wei X, Han H, Meng X, Zhang Y, Shi W, Li F, Xin T, Pang Q, Yi F: NLRP3 deficiency ameliorates neurovascular damage in experimental ischemic stroke. J Cereb Blood Flow Metab 2014;34:660-667.
8.
Tong Y, Ding ZH, Zhan FX, Cai L, Yin X, Ling JL, Ye JJ, Hou SY, Lu Z, Wang ZH, Liu JF: The NLRP3 inflammasome and stroke. Int J Clin Exp Med 2015;8:4787-4794.
9.
Zhu Z, Yan J, Geng C, Wang D, Li C, Feng S, Wang H: A polymorphism within the 3′UTR of NLRP3 is associated with susceptibility for ischemic stroke in the Chinese population. Cell Mol Neurobiol 2016;36:981-988.
10.
Fagan SC, Cronic LE, Hess DC: Minocycline development for acute ischemic stroke. Transl Stroke Res 2011;2:202-208.
11.
Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, Przedborski S: Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002;22:1763-1771.
12.
Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J: Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci 2001;21:2580-2588.
13.
Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, Sarang S, Liu AS, Hartley DM, Wu DC, Gullans S, Ferrante RJ, Przedborski S, Kristal BS, Friedlander RM: Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002;417:74-78.
14.
Longa EZ, Weinstein PR, Carlson S, Cummins R: Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989;20:84-91.
15.
Hayakawa K, Pham LD, Katusic ZS, Arai K, Lo EH: Astrocytic high-mobility group box 1 promotes endothelial progenitor cell-mediated neurovascular remodeling during stroke recovery. Proc Natl Acad Sci USA 2012;109:7505-7510.
16.
Hatashita S, Hoff JT, Salamat SM: Ischemic brain edema and the osmotic gradient between blood and brain. J Cereb Blood Flow Metab 1988;8:552-559.
17.
Wang P, Xu TY, Wei K, Guan YF, Wang X, Xu H, Su DF, Pei G, Miao CY: ARRB1/beta-arrestin-1 mediates neuroprotection through coordination of BECN1-dependent autophagy in cerebral ischemia. Autophagy 2014;10:1535-1548.
18.
Fan Y, Liu M, Wu X, Wang F, Ding J, Chen J, Hu G: Aquaporin-4 promotes memory consolidation in Morris water maze. Brain Struct Funct 2013;218:39-50.
19.
Liesz A, Suri-Payer E, Veltkamp C, Doerr H, Sommer C, Rivest S, Giese T, Veltkamp R: Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat Med 2009;15:192-199.
20.
Tuttolomondo A, Di Sciacca R, Di Raimondo D, Renda C, Pinto A, Licata G: Inflammation as a therapeutic target in acute ischemic stroke treatment. Curr Top Med Chem 2009;9:1240-1260.
21.
Aras M, Urfalı B, Serarslan Y, Ozgür T, Ulutaş KT, Urfalı S, Altaş M, Yılmaz N: Protective effects of minocycline against short-term ischemia-reperfusion injury in rat brain. Pediatr Neurosurg 2013;49:172-178.
22.
Zhao Y, Xiao M, He W, Cai Z: Minocycline upregulates cyclic AMP response element binding protein and brain-derived neurotrophic factor in the hippocampus of cerebral ischemia rats and improves behavioral deficits. Neuropsychiatr Dis Treat 2015;11:507-516.
23.
Jin Z, Liang J, Wang J, Kolattukudy PE: MCP-induced protein 1 mediates the minocycline-induced neuroprotection against cerebral ischemia/reperfusion injury in vitro and in vivo. J Neuroinflamm 2015;12:39.
24.
Walsh JG, Muruve DA, Power C: Inflammasomes in the CNS. Nat Rev Neurosci 2014;15:84-97.
25.
Li J, Chen J, Mo H, Chen J, Qian C, Yan F, Gu C, Hu Q, Wang L, Chen G: Minocycline protects against NLRP3 inflammasome-induced inflammation and p53-associated apoptosis in early brain injury after subarachnoid hemorrhage. Mol Neurobiol 2015;53:2668-2678.
26.
Fann DY, Lee SY, Manzanero S, Chunduri P, Sobey CG, Arumugam TV: Pathogenesis of acute stroke and the role of inflammasomes. Ageing Res Rev 2013;12:941-966.
27.
Nagasawa T, Arai M, Togari A: Inhibitory effect of minocycline on osteoclastogenesis in mouse bone marrow cells. Arch Oral Biol 2011;56:924-931.
28.
Chen DF, Gong BD, Xie Q, Ben QW, Liu J, Yuan YZ: MicroRNA155 is induced in activated CD4+ T cells of TNBS-induced colitis in mice. World J Gastroenterol 2010;16:854-861.
29.
Thounaojam MC, Kundu K, Kaushik DK, Swaroop S, Mahadevan A, Shankar SK, Basu A: MicroRNA 155 regulates Japanese encephalitis virus-induced inflammatory response by targeting Src homology 2-containing inositol phosphatase 1. J Virol 2014;88:4798-4810.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.